Indevus/Pliva Sanctura For Overactive Bladder Clears FDA; Third Quarter Launch Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus and Pliva will detail trospium with a sales force of approximately 480 reps under a co-promotion deal signed in April. The companies will face marketing powerhouses Pfizer (Detrol LA) and J&J (Ditropan XL).
You may also be interested in...
Sanctura XR NDA Filing On Target For Year-End
Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.
Sanctura XR NDA Filing On Target For Year-End
Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.
Indevus To Market Nebido In The U.S. Upon Approval
Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.